Patient characteristics by neoadjuvant cycles
| Variables | Whole cohort | 3 cycles | 4 cycles | ≥5 cycles | P value* |
| Patients (n) | 199 | 73 | 70 | 56 | |
| Age at diagnosis | |||||
| Median (mean) | 66.5 (66.5) | 66 (66.1) | 65.5 (65) | 68.6 (68.9) | 0.111 |
| Range | 43.1–87.9 | 43.1–86.4 | 43.2–87.2 | 45.1–87.9 | |
| Histology | |||||
| High-grade serous | 183 (92%) | 65 (89%) | 66 (94.3%) | 52 (92.9%) | 0.516 |
| Others† | 16 (8%) | 8 (11%) | 4 (5.7%) | 4 (7.1%) | |
| Stage | |||||
| III | 66 (33.2%) | 29 (39.7%) | 23 (32.9%) | 14 (25%) | 0.226 |
| IV | 133 (66.8%) | 44 (60.3%) | 47 (67.1%) | 42 (75%) | |
| BRCA status | |||||
| No mutation | 139 (69.8%) | 48 (65.8%) | 49 (70%) | 42 (75%) | 0.344 |
| BRCA1/2 mutation | 30 (15.1%) | 14 (19.2%) | 12 (17.1%) | 4 (7.1%) | |
| Not tested | 30 (15.1%) | 11 (15.1%) | 9 (12.9%) | 10 (17.9%) | |
| Charlson score (12 missing) | |||||
| Median (mean) | 8 (8.5) | 8 (8.4) | 8 (8.4) | 9 (8.6) | 0.451 |
| Range | 6–12 | 6–12 | 6–12 | 6–12 | |
| Chemotherapy regimen (12 missing) | |||||
| Weekly paclitaxel/carboplatin | 134 (71.7%) | 52 (77.6%) | 49 (73.1%) | 33 (62.3%) | 0.17 |
| Others | 53 (28.3%) | 15 (22.4%) | 18 (26.9%) | 20 (37.7%) | |
| Neoadjuvant indication‡* | |||||
| Patient factors | 60 (30.2%) | 28 (38.4%) | 16 (22.9%) | 16 (28.6%) | 0.13 |
| Disease factors | 139 (69.8%) | 45 (61.6%) | 54 (77.1%) | 40 (71.4%) | |
| Response on imaging after 2–3 pre-operative cycles | |||||
| Response | 181 (91%) | 68 (93.2%) | 66 (94.3%) | 47 (83.9%) | 0.116 |
| No response/progression | 18 (9%) | 5 (6.8%) | 4 (5.7%) | 9 (16.1%) | |
| Optimal debulking | |||||
| No | 18 (9%) | 8 (11%) | 5 (7.1%) | 5 (8.9%) | 0.745 |
| Yes | 181 (91%) | 65 (89%) | 65 (92.9%) | 51 (91.1%) | |
| Complete gross resection | |||||
| No | 60 (30.2%) | 23 (31.5%) | 21 (30%) | 16 (28.6%) | 0.962 |
| Yes | 139 (69.8%) | 50 (68.5%) | 49 (70%) | 40 (71.4%) | |
| Adjuvant therapy (4 missing) | |||||
| No | 15 (7.7%) | 1 (1.4%) | 3 (4.3%) | 11 (20%) | <0.001 |
| Yes | 180 (92.3%) | 69 (98.6%) | 67 (95.7%) | 44 (80%) | |
| Post-operative cycles | |||||
| Median (mean) | 3 (2.9) | 3 (3.2) | 3 (2.8) | 2 (2.4) | <0.001 |
| Range | 1–6 | 2–6 | 1–4 | 1–4 | |
*P values are obtained using the Kruskal–Wallis test for continuous variables and Fisher's exact test for categorical variables.
†Of the 16 women with other histologies, 2 had clear cell carcinoma, 1 had endometrioid, 2 had carcinosarcoma, 1 had low-grade serous, and 10 had Mullerian carcinoma (non-specific).
‡Patient factors include Aletti score, co-morbidity, venous thromboembolism, clinical trial, or other. Disease factors include stage IV unresectable, extent of disease on imaging, extent of disease on laparoscopy, extent of disease requiring thoracic surgery.